Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases.
Insmed stock last closed at $185.68, up 2.17% from the previous day, and has increased 164.61% in one year. It has overperformed other stocks in the Biotechnology industry by 2.23 percentage points. Insmed stock is currently +207.42% from its 52-week low of $60.40, and -5.78% from its 52-week high of $197.08.
As of Nov 6, 2025, there are 213.27M shares of INSM outstanding. The market cap of INSM is $39.60B. In the past 24 hours, 1.84M INSM shares were traded.
How to Buy Insmed Stock
Wondering how to invest in Insmed stock? Here's how.
Figure out where to buy Insmed stock: You need to pick a stock brokerage, but don't worry - we've researched dozens of stock brokerages and apps to help you choose where to buy Insmed stock.
Sign up for your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
Deposit funds into your brokerage account: Choose your method of payment and add your information.
Analyze Insmed stock: The Insmed ticker symbol is INSM. Is Insmed stock a good investment? Should you buy shares of INSM? How do INSM's underlying business fundamentals look? Do top analysts think Insmed is a good buy? Why has INSM's stock price moved recently? (Hint: Our stock market analysis website can help you understand if INSM is a good stock to buy).
Place your INSM buy order: Decide if you will purchase INSM shares at the current market price or use a limit order to purchase INSM shares at a given price.
Get updates on your investment in INSM: Create a watchlist to key updates about your investment in Insmed stock.
Step 1: Figure out where to buy Insmed stock
You will need a brokerage account to access the NASDAQ market and buy INSM stock.
A brokerage account is an investment account that allows you to buy and sell a number of investments, such as stocks, bonds, mutual funds, and ETFs.
Our favorite brokerage: eToro
Based on our experience, eToro is the best brokerage. Here's why:
You can invest in stocks with 0% commissions: Invest without paying trading commissions.
Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
Access to world markets: From Technology to Real Estate, New York to Hong Kong (for US users, only US stocks are available) ā you can fill your portfolio with stocks from the globe's leading stock exchanges.
Social investing: eToro has a community of more than 20 million users globally. Talk to, learn from, and copy the crypto trades of other investors.
Security: eToro is a regulated and licensed brokerage platform.
Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of stock by signing up for an account with eToro today. This offer is only for US users.
eToro securities trading is offered by eToro USA Securities, Inc. (āthe BDā), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (āthe MSBā) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Sign up for your brokerage account
Now that you've selected the best brokerage, it's time to fill out some personal details so you can buy INSM stock today.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Step 4: Analyze Insmed stock
Once you have identified the best place to buy Insmed stock, it's very important to evaluate their stock prior to buying, so you actually comprehend the risk as well as the upside.
Insmed shares at a glance
INSM Price
$185.68
1w %
0.05%
1y %
164.61%
5y %
465.09%
P/E
-30.09x
P/B
41.88x
P/S
87.96x
PEG
N/A
Revenue
$447.02M
Earnings
-$1.18B
Fore. Rev. Growth
67.06%
Fore. Earn. Growth
N/A
Market Cap
$39.60B
Next Earnings
N/A
Next Dividend
N/A
INSM Due Diligence Checks
WallStreetZen was created to help average investors perform better fundamental analysis.
INSM has cash burn of 906141000. It has enough cash and short-term investments to cover this for at least one year.
There are more short-term assets than short-term liabilities on the INSM balance sheet.
There are more short-term assets than long-term liabilities on the INSM balance sheet.
Failed Financial Due Diligence Checks:
INSM has $1.68B in cash and short term investments. This is not enough to cover its annual cash burn of $906.14M.
Total INSM debt is higher than 5 years ago, relative to shareholder equity.
INSM profit margin has gone down from -252% to -264.8% in the past year.
INSM has a relatively high debt to equity ratio of 1.5.
Is it a good time to buy Insmed stock, according to analysts?
Out of 17 Equities analysts who give recommendations on INSM, the consensus analyst rating on INSM is a Strong Buy
It's important to note that analyst forecasts are not stock recommendations, nor are they financial advice.
Latest INSM Analyst Upgrades/Downgrades
Ritu Baral, a top 37% analyst from TD Cowen maintains INSM with a strong buy rating and raises their INSM price target from $154.00 to $193.00, on Oct 2, 2025.
Vamil Divan, a top 3% analyst from Guggenheim maintains INSM with a strong buy rating and raises their INSM price target from $125.00 to $172.00, on Sep 8, 2025.
Guggenheim's Vamil Divan raised their price target on Insmed (NASDAQ: INSM) by 37.6% from $125 to $172 on 2025/09/08. The analyst maintained their Strong Buy rating on the stock.
Divan attributed their price target hike on Insmed to:
Increasing their Brinsupri non-cystic fibrosis bronchiectasis revenue estimate.
Adding revenue estimates for TPIP in IPF.
And, lowering its terminal decline rate because of added confidence in the long-term potential of the company's pipeline.
Maxwell Skor, a top 46% analyst from Morgan Stanley maintains INSM with a hold rating and raises their INSM price target from $126.00 to $144.00, on Aug 21, 2025.
Jessica Fye, a top 4% analyst from JP Morgan maintains INSM with a strong buy rating and raises their INSM price target from $111.00 to $135.00, on Aug 20, 2025.
Nicole Germino, a top 13% analyst from Truist Securities maintains INSM with a strong buy rating and raises their INSM price target from $126.00 to $139.00, on Aug 14, 2025.
You can dive deeper into what analysts are saying on the Insmed stock forecast page.
INSM Technical Indicators
SMA10
181.13
SMA20
172.13
SMA50
157.32
SMA100
133.69
SMA200
104.45
MACD
9.5
MACD Signal
8.27
MACD Histogram
1.23
RSI
70.24
Stochastic %K
77.16
Stochastic %D
73.66
StochRSI %K
46.96
StochRSI %D
45.64
INSM Growth Metrics
Last year, INSM revenue was $447.02M. During the past 5 year, INSM's revenue has gone up by 21.52% per year. This was slower than the Biotechnology industry average of 53.59%.
No, Insmed doesn't provide an income stream by paying out dividends.
What do other investors have to say about INSM?
One of the primary reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to learn what other community members have to say.
Step 5: Place your INSM buy order
There are two main order types:
Market order: A market order is an order to buy or sell a security at the best price on the market. Market orders are mostly the easiest way to buy.
Limit order: A limit order lets you buy or sell a stock at a specific price (or better). If you want to be certain you're buying or selling at a particular dollar amount, place a limit order.
Hit the Open Trade button and your broker will place your order.
If you require more help with buying stocks on eToro, click the helpful video below:
As of Nov 6, 2025, it costs $185.68 to buy one share of Insmed stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $100, you can buy 0.539 shares of INSM.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.